Navigation Links
Hope for a new treatment for bone cancer
Date:10/12/2010

Children and young people who are diagnosed with bone cancer could benefit from better treatment in the future thanks to new research at The University of Nottingham.

The Bone Cancer Research Trust launches Bone Cancer Awareness Week today and has funded a new project at the University which is testing a theory that 'friendly bacteria' can be used to kill bone cancer cells.

Researchers at the School of Clinical Sciences' Division of Pre-Clinical Oncology are investigating whether modifying a harmless type of the bacterium, Salmonella typhimurium, can produce molecules which kill cancer cells in osteosarcoma, a primary bone cancer. The scientists are using a clinically safe form of the bacterium which has been found to localise to tumour tissue rather than healthy tissue.

Leading the research, Dr Teresa Coughlan, said: "Developing a treatment that effectively targets cancer cells, but doesn't damage healthy cells is the Holy Grail for bone cancer treatment. We are excited by this project as potentially it could result in a new treatment for osteosarcoma, which typically has a poor prognosis."

Osteosarcoma (OS) is the most common type of primary bone cancer and although rare, can be particularly distressing because it affects mostly children and adolescents. Cases tend to have a poor outlook because the cancer often does not respond well to the treatments currently available. There have been few new treatments for OS in the past 20 years and more research and techniques to fight it are urgently needed as more than 2,000 children and young people are diagnosed with the disease every year in the UK.

A main challenge in developing better treatments for bone cancer is finding a much more effective way of targeting anti-cancer drugs at the tumour. Many drugs are given by intravenous injection and use the body's venous system to reach their target, but tumours in bone tend to have a low blood supply.

Dr Coughlan's
'/>"/>

Contact: Emma Rayner
emma.rayner@nottingham.ac.uk
44-115-951-5793
University of Nottingham
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. Women More Likely to Fail Treatment for Atrial Fibrillation
3. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Nanofilm Introduces Clarity Defog It™ Anti Fog Treatment and EcoClens™ Eco-Friendly Lens Cleaner at Vision Expo East
6. Many veterans not getting enough treatment for PTSD
7. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
8. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
9. Charging less for more effective treatments could reduce health care costs while improving health
10. Added Drug Aids MS Treatment
11. PTSD Treatment Still Lacking for Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Va. (May 22, 2012) Scientists at ... one step closer to developing a new therapy ... the targeted agents obatoclax and sorafenib kill leukemia ... the drugs are administered individually., Recently published in ... led by Steven Grant, M.D., Shirley Carter Olsson ...
(Date:5/22/2012)... Women who are unable to quit smoking ... of their newborns by taking Vitamin C daily, ... & Science University Doernbecher Children,s Hospital. , "Smoking ... lung development of the developing baby, causing lifelong ... asthma," said Cindy McEvoy, M.D., M.C.R., neonatologist and ...
(Date:5/22/2012)... at UC Davis have developed a microfluidic chip to ... be cheaper, faster and more reliable than current testing ... and gives results in real time," said Ying Liu, ... the UC Davis Department of Biomedical Engineering. , The ... patients in China and the United States. , About ...
(Date:5/22/2012)... hypersensitivity reactions to the anti-HIV drug abacavir occur through ... immunogens that are attacked by the body,s immune system, ... AIDS , official journal of the ... published by Lippincott Williams & Wilkins , a ... study is the first to explain how hypersensitivity reactions ...
(Date:5/22/2012)... 22 (HealthDay News) -- Certain gene variants linked ... to lower urinary tract symptoms, according to a ... gene variant might protect against those symptoms, the ... School of Medicine at Northwestern University in Chicago ... cancer risk in nearly 2,000 healthy, white men ...
Breaking Medicine News(10 mins):Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3Health News:Vitamin C improves lung function in newborns of pregnant smoking women 2Health News:New TB test promises to be cheap and fast 2Health News:Reactions to HIV drug have autoimmune cause, reports AIDS journal 2Health News:Reactions to HIV drug have autoimmune cause, reports AIDS journal 3Health News:Study Ties Genes to Lower Urinary Tract Symptoms, Prostate Cancer Risk 2
... CHAPEL HILL, N.C., April 16 Top Performers ... and,efficiency data -- when-possible and submit them for ... to raise awareness on key,humanistic and Quality of ... evidence based Guidelines and customize to managed care,organizations., ...
... Provide Revenue Cycle Solutions for ... Historic, 150 Year-Old Institution, PLANO, Texas, ... announced a new seven-year Revenue Cycle,Solutions agreement with New York ... Cycle Solutions that will,provide management and patient financial service professionals ...
... for aggressive breast cancer,Well-documented breast cancer tissue collection meets ... , Mammography and biopsies help find breast cancer, but ... will spread. Now, a two-year research project hopes to ... patients harboring not just breast cancer, but the nastiest ...
... Jenni Schaefer, a young,woman in Tennessee who ... to become a well-known motivational speaker, author, singer,songwriter ... been,appointed to the Ambassador Council of the National ... Schaefer will continue her travels nationally and,internationally, speaking ...
... According to New NCPA,Study, DALLAS, April 16 ... on low-income workers when they work,extra hours to get ... Center for Policy Analysis., "The impact on low-income ... Fellow Laurence Kotlikoff, Boston University,professor and author of the ...
... As potential cancer therapies proliferate, researchers and clinicians ... accurately predict which patients will receive the most benefit. ... Annual Meeting, April 12-16, 2008, researchers present data on ... doctors can more effectively measure response to commonly used ...
Other Medicine News:Health News:Perot Systems Selected to Implement Revenue Cycle Solution for New York Downtown Hospital 2Health News:Perot Systems Selected to Implement Revenue Cycle Solution for New York Downtown Hospital 3Health News:Research collaboration seeks blood test for aggressive breast cancer 2Health News:Research collaboration seeks blood test for aggressive breast cancer 3Health News:Jenni Schaefer, Motivational Speaker, Author Named National Eating Disorders Association (NEDA) Ambassador 2Health News:Tax Rates Mean Extra Work Doesn't Pay 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 2Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 3Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 4Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 5Health News:Measuring medicine: How new technologies could help doctors predict patient outcomes 6
(Date:5/22/2012)... ThermoGenesis Corp. (NASDAQ: KOOL ), a leading ... administration of cell therapies, today said that it received ... (AXP) used for the processing of cord blood. The ... the country later this year. "We already ... market through our efforts in China, Malaysia and India, ...
(Date:5/22/2012)... 22, 2012  Comprehensive Care Corporation ("CompCare") (OTC ... and psychotropic pharmacy management services provider for managed ... its revenues for the first quarter of 2012 ... totaled $80,000 for the quarter. ... a profit, albeit modest, for its first quarter ...
(Date:5/22/2012)... 2012 Sorbent Therapeutics, Inc. a biopharmaceutical ... presented positive data from its Phase 2a clinical ... heart failure patients with chronic kidney disease, CLP1001 ... to placebo.    Data from the ... an oral session at the Annual European Society ...
Breaking Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Comprehensive Care Corporation Announces Profit for First Quarter 2Comprehensive Care Corporation Announces Profit for First Quarter 3Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 2Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study 3MU veterinarians find infections faster by monitoring blood compound 22749 1How muscle fatigue originates in the head 87531 1How muscle fatigue originates in the head 87531 2Oxidative stress 3A Less harmful than suspected 3F 22747 1Oxidative stress 3A Less harmful than suspected 3F 22747 2
... 2007 - An evaluation of the,safety and effectiveness ... vaginal atrophy, a frequent complaint of,postmenopausal women, has ... (NAMS). Entitled "The role of local vaginal,estrogen for ... statement of The North American Menopause Society,",the document ...
... CORAL GABLES, Fla., May 09, 2007 /PRNewswire-FirstCall/ ... top-line results from a bioequivalence study demonstrating,that ... to Sabril Tablets, the version of vigabatrin ... potentially provide a basis,for linking CPP-109 to ...
Other Medicine Technology:New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 2New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women 3Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results,of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's,Investigational Drug to Treat Cocaine and Methamphetamine Addiction 4
... from Thermo Labsystems was designed specifically to ... features such as the new fast dial ... microvolumes help to define this as a ... new interchangeable handle plate offers a custom ...
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
Medicine Products: